2. Search Result
Search Result
Results for "

KV7.1/KCNE1

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

1

Natural
Products

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17442
    Azathramycin

    Azaerythromycin A; Desmethyl Azithromycin

    		 Bacterial Antibiotic Infection
    Azathramycin (Desmethyl Azithromycin) is a macrolide antibiotic. Azathramycin is a derivative of the anti-ribosomal antibiotic Azithromycin (HY-17506). Azathramycin exerts its antibacterial activity by binding to ribosomes and inhibiting bacterial protein synthesis. Azathramycin can selectively target and kill human senescent fibroblasts and is expected to be used in anti-aging research. Azathramycin affects multiple ion channels such as SCN5A, hERG, KCNQ1 + KCNE1, L-type Ca ++ and Kir2.1 [1] .
    Azathramycin
  • HY-18063
    ML252

    		Potassium Channel Cytochrome P450 Neurological Disease
    ML252 is a selective inhibitor of KCNQ2 (Kv7.2) channel with an IC50s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 also inhibits Cytochrome P450 with IC50s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant [1] .
    ML252
  • HY-108591
    L-364,373

    R-L3

    		 Potassium Channel Cardiovascular Disease
    L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes [1].
    L-364,373
  • HY-108577
    XE991 dihydrochloride
    3 Publications Verification

    		 Potassium Channel Neurological Disease
    XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively [1].
    XE991 dihydrochloride
  • HY-108577A
    XE991
    3 Publications Verification

    		 Potassium Channel Neurological Disease
    XE 991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively [1].
    XE991
  • HY-108584
    Flindokalner

    BMS-204352

    		 Potassium Channel Neurological Disease
    Flindokalner (BMS-204352) is a potassium channel modulator. Flindokalner is a positive modulator of all neuronal Kv7 channel subtypes expressed in HEK293 cells. Flindokalner is also a large conductance calcium-activated K channel (BKca) positive modulator. Flindokalner shows a negative modulatory activity at Kv7.1 channels (Ki=3.7 μM), and acts as a negative modulator of GABAA receptors. Flindokalner shows anxiolytic efficacy in vivo [1] .
    Flindokalner
  • HY-RS07115
    KCNE1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KCNE1 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KCNE1 Human Pre-designed siRNA Set A
    KCNE1 Human Pre-designed siRNA Set A
  • HY-122504
    Linoleoyl glycine

    		Potassium Channel Neurological Disease
    Linoleoyl glycine is a modified polyunsaturated fatty acid. Linoleoyl glycine has activating effects on human KCNQ1/KCNE1 (hKCNQ1/hKCNE1) channels expressed in Xenopus oocytes [1].
    Linoleoyl glycine
  • HY-18063A
    ML252 hydrochloride

    		Potassium Channel Cytochrome P450 Neurological Disease
    ML252 hydrochloride is a selective inhibitor of KCNQ2 (Kv7.2) channel with IC50s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 hydrochloride also inhibits Cytochrome P450 with IC50s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 hydrochloride shows highly brain penetrant [1] .
    ML252 hydrochloride
  • HY-108577R
    XE991 dihydrochloride (Standard)

    		Potassium Channel Neurological Disease
    XE991 dihydrochloride (Standard) is the analytical standard of XE991 dihydrochloride. This product is intended for research and analytical applications. XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively [1].
    XE991 dihydrochloride (Standard)
  • HY-108584R
    Flindokalner (Standard)

    		Potassium Channel Neurological Disease
    Flindokalner (Standard) is the analytical standard of Flindokalner. This product is intended for research and analytical applications. Flindokalner (BMS-204352) is a potassium channel modulator. Flindokalner is a positive modulator of all neuronal Kv7 channel subtypes expressed in HEK293 cells. Flindokalner is also a large conductance calcium-activated K channel (BKca) positive modulator. Flindokalner shows a negative modulatory activity at Kv7.1 channels (Ki=3.7 μM), and acts as a negative modulator of GABAA receptors. Flindokalner shows anxiolytic efficacy in vivo [1] .
    Flindokalner (Standard)
  • HY-12343
    ML277

    CID-53347902

    		 Potassium Channel Cardiovascular Disease
    ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes [1] .
    ML277
  • HY-121520
    Docosahexaenoyl glycine

    		Potassium Channel Endogenous Metabolite Cardiovascular Disease
    Docosahexaenoyl glycine is a PUFA analogue. Docosahexaenoyl glycine has activating effects on IKs channels and restore the function of IKs channels with LQT1 mutation [1].
    Docosahexaenoyl glycine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: